FINWIRES · TerminalLIVE
FINWIRES

$TECH

6 stories mentioning TECH

Every FINWIRES story that references TECH, newest first.

Wire

Market Chatter: Bio-Techne Faces Pressure From Ananym Capital to Explore Sale

Bio-Techne (TECH) received a push from activist investor Ananym Capital Management to conduct a strategic review, including a potential sale, Bloomberg reported Monday, citing a letter the media outlet reviewed.In the letter to the board, Ananym argued a sale to a larger industry player would deliver more value than Bio-Techne can achieve as a standalone company, the report said.Ananym has built a stake in the life sciences company, according to the report.Bio-Techne did not immediately respond to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $55.92, Change: $+1.92, Percent Change: +3.55%

$TECH
Research

Piper Sandler Initiates Bio-Techne at Neutral With $65 Price Target

Bio-Techne (TECH) has an average rating of overweight and mean price target of $61.55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TECH
Wire

Bio-Techne's Planned Wilson Wolf Acquisition Underappreciated by Investors, RBC Says

Bio-Techne's (TECH) planned full acquisition of Wilson Wolf is underappreciated by the market, despite its expected boost to Bio-Techne's exposure to cell therapy, RBC Capital Markets said in a note Thursday.Bio-Techne owns 20% of the cell therapy tools company and plans to fully acquire it by the end of 2027. Assuming that Wilson Wolf maintains its double-digit growth and 70% plus earnings before interest, taxes, depreciation and amortization margins, and the deal is viewed as a "jewel" at about 4.4x trailing sales, the analyst said.It adds over 100 basis points to Bio-Techne's structural growth and increases its exposure to the cell therapy market to about 15% of sales, the highest in RBC's coverage, despite mixed early results in cell therapy, with activity and pipelines still strong, the analyst said."And when the market is ready to look out to 2027, we think investors will wake up to the transformative acquisition of Wilson Wolf that is not yet fully appreciated," the analyst added.RBC resumed coverage of Bio-Techne with an outperform rating and a $62 price target.Price: $44.78, Change: $+0.04, Percent Change: +0.09%

$TECH
Insider Trading

Bio-Techne Insider Sold Shares Worth $320,386, According to a Recent SEC Filing

Amy E. Herr, Director, on May 08, 2026, sold 6,636 shares in Bio-Techne (TECH) for $320,386. Following the Form 4 filing with the SEC, Herr has control over a total of 2,880 shares of the company, with 2,680 common shares held directly and 200 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/842023/000091419026000092/xslF345X05/form4.xml

$TECH
Research

Research Alert: CFRA Lowers Rating On Shares Of Bio-techne Corporation To Sell From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target is $44, down from $59, 21.2x our FY 27 EPS estimate. Our multiple is below TECH's one-year historical forward average of 26.1x and the three-year average of 30.7x. We lower our FY 26 EPS estimate by $0.06 to $1.92 and our FY 27 estimate by $0.09 to $2.08. Along with peers, shares have been under pressure due to concerns around NIH and U.S. academic research funding, an important end market for the company, as well as a slowly recovering biotech funding environment. Though we see some indications of improving conditions, we prefer some of TECH's larger, more diversified peers over the near term and think shares are more likely to underperform despite expected sales/EPS growth. We note multiple recent quarters of growth for the large pharma end market and China/APAC sales. Similar to recent commentary from life sciences tools and services peers, TECH sees indications of improving biotech funding, as well as licensing and M&A activity, heading into FY 27.

$TECH
Research

Research Alert: Bio-techne: U.s. Academia Grows Modestly, Q3 Fy 26 Eps Meets Consensus

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Bio-Techne delivered Q3 FY 26 (Jun.) adjusted EPS of $0.53, in-line with consensus, while sales declined 2% to $311.4M amid challenging conditions and unfavorable Commercial Supply timing. Double-digit pharma growth for the sixth consecutive quarter helped offset the gradually recovering biotech funding environment. We believe the company's diversified portfolio and strong financial flexibility position Bio-Techne to capitalize on improving market conditions. Management expressed cautious optimism about improving end-market fundamentals, noting early indicators of better alignment between biotech funding and customer purchasing. U.S. academic markets showed stabilization with low-single-digit growth, representing improvement from recent weakness. Protein Sciences revenue declined 1% to $226.2M with 44.2% operating margin, while Diagnostics and Spatial Biology revenue fell 4% to $85.6M but operating margin improved to 12.1% following the Exosome divestiture.

$TECH